公开(公告)号：US12226396B2

公开(公告)日：2025-02-18

申请号：US18163321

申请日：2023-02-02

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K31/366 ,  A61K9/00 ,  A61K31/191 ,  A61K31/765 ,  A61K45/06 ,  A61P31/04

Abstract: Pharmaceutical compositions and methods of using said pharmaceutical compositions are provided herein. A method of preventing preterm birth in a pregnant individual is also provided, said method comprising administering to said individual a pharmaceutical composition comprising a compound of Formula XX or a lactone thereof of formula XIX or XXI and preventing said preterm birth by said administration.

公开(公告)号：US20250049881A1

公开(公告)日：2025-02-13

申请号：US18602930

申请日：2024-03-12

Applicant: Bausch Health Ireland Limited

Inventor： Stephen Comiskey ,  Rong Feng ,  John Foss ,  Kunwar Shailubhai

IPC: A61K38/10 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/192 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/765 ,  A61K31/78 ,  A61K38/12 ,  A61K45/06 ,  A61K47/12 ,  A61K47/38 ,  C07K7/08 ,  C07K7/54 ,  C07K7/64

Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

公开(公告)号：US12194059B2

公开(公告)日：2025-01-14

申请号：US17691518

申请日：2022-03-10

Applicant: Board of Regents, The University of Texas System

Inventor： Jian Yang

IPC: A61K31/785 ,  A61K31/765 ,  A61K33/42 ,  C08G63/12 ,  C08G63/91 ,  C08G81/00 ,  C08L67/04 ,  C12N5/077

Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.

公开(公告)号：US20240415876A1

公开(公告)日：2024-12-19

申请号：US18792849

申请日：2024-08-02

Applicant: Braintree Laboratories, Inc.

Inventor： Edmund V. Dennett ,  Mark Cleveland ,  Russell W. Pelham ,  Matthew Walker

IPC: A61K31/765 ,  A61K9/08 ,  A61K33/04 ,  A61K47/02 ,  A61K47/26 ,  A61P1/10

Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

公开(公告)号：US20240293444A1

公开(公告)日：2024-09-05

申请号：US18653713

申请日：2024-05-02

Applicant: MedinCell S.A.

Inventor： Christophe ROBERGE ,  Adolfo LÓPEZ-NORIEGA ,  Jean-Manuel CROS ,  Juliette SERINDOUX ,  Murielle OSTER ,  Fang LIU ,  Charlotte MOLINIER ,  Sylvestre GRIZOT ,  Tjasa VRLINIC ,  Feifei NG ,  Elise GUÉGAIN ,  Marie-Emérentienne CAGNON

IPC: A61K31/765 ,  A61K9/00 ,  A61K31/445 ,  A61K31/4985 ,  A61K31/5415 ,  A61K31/675 ,  A61K31/7048 ,  A61K47/34

CPC classification number: A61K31/765 ,  A61K9/0024 ,  A61K31/445 ,  A61K31/4985 ,  A61K31/5415 ,  A61K31/675 ,  A61K31/7048 ,  A61K47/34

Abstract: The present invention provides a pharmaceutical composition comprising:
a biodegradable multi-branched copolymer comprising at least three polyester arms attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient.

公开(公告)号：US20240269163A1

公开(公告)日：2024-08-15

申请号：US18567972

申请日：2022-06-08

Applicant: The Texas A&M University System ,  The Trustees of Indiana University

Inventor： Thomas A. KENT ,  Paul J. DERRY ,  Kenneth R. OLSON

IPC: A61K31/765 ,  A61K9/00 ,  A61K31/385 ,  A61K47/69 ,  A61P43/00

CPC classification number: A61K31/765 ,  A61K9/0053 ,  A61K31/385 ,  A61K47/6921 ,  A61P43/00

Abstract: A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.

公开(公告)号：US12036236B2

公开(公告)日：2024-07-16

申请号：US17507170

申请日：2021-10-21

Applicant: International Business Machines Corporation ,  Agency for Science, Technology and Research

Inventor： James L. Hedrick ,  Yi Yan Yang ,  Nathaniel H. Park ,  Victoria A. Piunova ,  Zhi Xiang Voo

IPC: A61K31/765 ,  A61K31/155 ,  C08K5/31 ,  C08L69/00

CPC classification number: A61K31/765 ,  A61K31/155 ,  C08K5/31 ,  C08L69/00

Abstract: Compositions and methods regarding antimicrobial guanidinium macromolecules with one or more targeting moieties for selectively targeting bacteria are provided. According to an embodiment, an antimicrobial macromolecule is provided that comprises a polymer backbone and one or more guanidinium moieties that extend from the polymer backbone. The antimicrobial macromolecule further comprises a targeting moiety that extends from the polymer backbone. The targeting moiety can comprise a substance favored for consumption by bacteria, such as a monosaccharide.

公开(公告)号：US20240000830A1

公开(公告)日：2024-01-04

申请号：US18330319

申请日：2023-06-06

Applicant: onCour Pharma, Inc.

Inventor： Daniel R. GETTS

IPC: A61K31/78 ,  A61K9/00 ,  A61K39/00 ,  A61K39/39 ,  A61K31/01 ,  A61K31/74 ,  A61K31/765 ,  G01N33/68 ,  A61P35/00 ,  A61K9/14 ,  A61K31/00 ,  A61K9/16

CPC classification number: A61K31/78 ,  A61K9/0019 ,  A61K39/001 ,  A61K39/39 ,  A61K31/01 ,  A61K31/74 ,  A61K31/765 ,  G01N33/6893 ,  A61P35/00 ,  A61K9/14 ,  A61K39/0005 ,  A61K31/00 ,  A61K9/146 ,  A61K9/1647 ,  G01N2800/7095 ,  A61K2039/55555 ,  Y02A50/30

Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.

公开(公告)号：US20230355660A1

公开(公告)日：2023-11-09

申请号：US18246122

申请日：2021-09-23

Applicant: ABLEVIA BIOTECH GMBH

Inventor： Oskar SMRZKA ,  Bettina WANKO

IPC: A61K31/765 ,  A61K47/60 ,  A61P37/06

CPC classification number: A61K31/765 ,  A61K47/60 ,  A61P37/06

Abstract: A compound for the sequestration of undesirable anti-polyethylene glycol (PEG) antibodies interfering with therapy by PEGylated active agents (such as PEGylated enzymes or antibodies) in a patient is provided. The compound includes an inert biopolymer scaffold and one or more PEG chains. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more anti-PEG antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with a PEGylated active agent.

公开(公告)号：US20230302043A1

公开(公告)日：2023-09-28

申请号：US18143026

申请日：2023-05-03

Applicant: Locke Davenport HUYER ,  Miles MONTGOMERY ,  Milica RADISIC

Inventor： Locke Davenport HUYER ,  Miles MONTGOMERY ,  Milica RADISIC

IPC: A61K31/765 ,  C08L67/02 ,  A61L27/38 ,  A61K9/00 ,  A61P29/00 ,  A61P31/04 ,  A61K31/047

CPC classification number: A61K31/765 ,  A61K9/0024 ,  A61K31/047 ,  A61L27/3839 ,  A61P29/00 ,  A61P31/04 ,  C08L67/02 ,  A61K2123/00 ,  C08L2312/06

Abstract: A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).